The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44.

Saved in:
Bibliographic Details
Title: The growth of a xenograft breast cancer tumor model with engineered hyaluronan-accumulating stroma is dependent on hyaluronan and independent of CD44.
Authors: Zhao C; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Thompson BJ; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Chen K; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Gao F; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Blouw B; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Marella M; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Zimmerman S; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Kimbler T; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Garrovillo S; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Bahn J; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Huang L; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Huang Z; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Shepard HM; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Rosengren S; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Thanos CD; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.; Formerly of Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA., Maneval DC; Halozyme Therapeutics, Inc., San Diego, CA, 92121, USA.
Source: Oncotarget [Oncotarget] 2019 Nov 12; Vol. 10 (61), pp. 6561-6576. Date of Electronic Publication: 2019 Nov 12 (Print Publication: 2019).
Publication Type: Journal Article
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1949-2553
DOI:10.18632/oncotarget.27302